Thus, VEGF is a therapeutic candidate for NP–C that influences sphingosine storage via SphK modulation, suggesting that enhancing SphK activity is a potential therapeutic intervention for this disorder. This evidence concerns the gene VEGFA and nasopharyngeal carcinoma.